SPOTLIGHT: The top five layoffs of 2007


2007 has been a rough year for a number of the pharmaceutical and biotech industry's biggest players. Concerns about patent expirations, falling sales due to drug safety concerns, redundancy from acquisitions and a general need to streamline operations contributed to these companies' decisions to cut employees. Check out this list of the top five pharma and biotech layoffs of 2007. Report

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.